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Abstract
Background: Obesity is a rising global threat to health and a major contributor to health inequalities. Weight
management programmes that are effective, economical and reach underprivileged groups are needed. We
examined whether a multi-modal group intervention structured to cater for clients from disadvantaged
communities (Weight Action Programme; WAP) has better one-year outcomes than a primary care standard weight
management intervention delivered by practice nurses (PNI).
Methods: In this randomised controlled trial, 330 obese adults were recruited from general practices in London
and allocated (2:1) to WAP (N = 221) delivered over eight weekly group sessions or PNI (N = 109) who received four
sessions over eight weeks. Both interventions covered diet, physical activity and self-monitoring. The primary
outcome was the change in weight from baseline at 12 months. To indicate value to the NHS, a cost effectiveness
analysis estimated group differences in cost and Quality-Adjusted Life-Years (QALYs) related to WAP.
Results: Participants were recruited from September 2012 to January 2014 with follow-up completed in February 2015.
Most participants were not in paid employment and 60% were from ethnic minorities. 88% of participants in each
study arm provided at least one recorded outcome and were included in the primary analysis. Compared
with the PNI, WAP was associated with greater weight loss overall (− 4·2 kg vs. − 2·3 kg; difference = − 1·9 kg,
95% CI: -3·7 to − 0·1; P = 0·04) and was more likely to generate a weight loss of at least 5% at 12 months
(41% vs. 27%, OR = 14·61 95% CI: 2·32 to 91·96, P = 0·004). With an incremental cost-effectiveness ratio (ICER)
of £7742/QALY, WAP would be considered highly cost effective compared to PNI.
Conclusions: The task-based programme evaluated in this study can provide a template for an effective and
economical approach to weight management that can reach clients from disadvantaged communities.
Trial registration: ISRCTN ISRCTN45820471. Registered 12/10/2012 (retrospectively registered).
Keywords: Weight management, Obesity, Weight loss, Cost-effectiveness
Background
Obesity is a rising global threat to health [1] with
concomitant increases in social, medical, and public
health costs. In the UK 10% of morbidity and mortal-
ity in the UK [2] can be attributed to obesity and
contributes to health inequalities, with rates higher in
lower socioeconomic groups [3]. The picture in other
developed countries is similar [4].
When compared to usual care, brief interventions in
primary care that encourage people to enrol in a weight
management service are found to provide approximately
1.5 kg weight loss within a year, [5]. In people unable to
lose weight on their own, surgical interventions can be
highly effective, but they are associated with considerable
costs and cannot be easily provided to large numbers of
people [6]. Existing pharmacological treatments have
more limited effects [7]. Stand-alone dietary interventions
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have only limited effects [8], and brief routine inter-
ventions within primary care show very little change
[9]. Behavioural interventions that are more intensive
show minimal but sustainable weight loss [10]. The most
recent meta-analyses of behavioural approaches reported a
pooled mean difference in weight loss for intervention ver-
sus control comparisons at 12months of 2·8 kg (95% CI
2.1 to 3·6 kg) [11], while in trials conducted in an ‘everyday
context’ via commercial weight loss programmes the differ-
ence in weight loss was 2·2 kg (95% CI 1·5 to 2·9 kg) [12].
These effects are modest but sustainable, and they are
sufficient to lead to long-term health improvements [13].
The majority of studies in this field have focused on par-
ticipant groups from middle to high socioeconomic groups
and disadvantaged and ethnic minority groups, that have in-
creased risk for obesity, are rarely represented [14]. This is
the case particularly for multi-component lifestyle treatments
that typically place considerable demands on participants’
engagement, understanding and commitment and some-
times also on their resources. There are however exceptions.
For example, around 73% of participants in the Lighten Up
study were from the bottom two quintiles of deprivation
[15]. Another is the Counterweight programme, which has
been implemented in a range of healthcare settings in the
UK and enrolled people from a mix of social and ethnic
backgrounds. Evaluations of this programme [16–18] have
reported weight loss of ≥5% in 30–35% of people that com-
pleted 12-month follow-up. However, this programme has
not been evaluated in a randomized controlled trial.
There is a need for weight management programmes that
are effective and attractive for patients from disadvantaged
communities. Basing a weight management course on sim-
ple and manageable tasks that are regularly monitored can
address some of the problems that complex multicompo-
nent programmes can pose. The present trial aimed to de-
termine the clinical- and cost-effectiveness of targeting a
disadvantaged population with a multi-modal task-based
group intervention (Weight Action Programme), which has
shown encouraging short-term results previously [19],
has an effect at one year that is better than a ‘best
practice’ weight management intervention provided by
practice nurses.
Methods
Study design
We conducted a two-arm, parallel-group randomised con-
trolled trial, with 12months follow-up, in general practices
in the London inner city boroughs of Tower Hamlets and
Hackney, the two most economically deprived boroughs in
London [20]. Ethical approval was granted from the
London - Central Ethics Committee (ref: 12/LO/0122).
The study protocol can be accessed via https://www.jour-
nalslibrary.nihr.ac.uk/programmes/hta/0912734#/ and the
funder report contains further details on the study [21].
Participants
We recruited adults (aged ≥18 years) living in the study
areas who had BMI ≥ 30 kg/m2 or a BMI of ≥28 kg/m2
with co-morbidities (criteria for referring patients for
weight loss interventions in the UK). Exclusion criteria
included not speaking English, BMI > 45, losing > 5% of
their body weight in the previous 6months, pregnancy,
and currently taking a psychiatric medication (because of
medication effects on weight). No other co-morbidities
were excluded to ensure that the study addressed the
needs of the National Health Service (NHS) and the re-
sults are generalisable to target populations.
Participants were recruited via fax referrals, posters,
flyers, and mailshots at two large local GP practices (one
in each borough), via referral from four neighbouring
GP practices, posters and leaflets at local community
venues, and three advertisements in the local press.
Randomisation and masking
Participants were randomised 2:1 (WAP:PNI) using per-
muted blocks which randomly varied in size (18, 21, and
24) and were stratified by the two GP sites. Randomisa-
tion was conducted using an independent online server
based at the University of Sheffield. Investigators rando-
mising participants were blind to the allocation until
they performed the randomisation. Staff collecting out-
comes were blind to participant allocation.
Procedures
At first contact (via telephone) participants received infor-
mation about the study and were screened for eligibility.
Eligible participants were sent (via post or email) the par-
ticipant information sheet, the baseline questionnaire, and
an invitation to the first study session a few days later. At
this session participants provided written informed con-
sent and baseline assessment was undertaken. A few
days later participants attended to complete question-
naires and provide other measures and to be rando-
mised. The first session of WAP and PNI took place
7–14 days after randomisation.
Both interventions were delivered over eight weeks,
with follow-ups scheduled at 6 and 12 months post-
randomisation. Participants were recruited from September
2012 to January 2014 with 1-year follow-ups com-
pleted in February 2015. Participants invited to attend
follow-up were offered £10 toward travel expenses.
Interventions
Weight action Programme (WAP)
WAP is a task-based multi-modal group intervention
that over a number of years has been modified through
client feedback to tailor it to appeal to disadvantaged
groups and has produced encouraging results in two
pilot studies [19].
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WAP aims to provide clear and simple advice on diet,
physical activity and self-monitoring via a range of con-
crete and verifiable tasks agreed individually with each
participant, as opposed to providing written and verbal
advice as is typically done (see Practice Nurse Interven-
tion). Where printed information is provided, it is mostly
in pictorial and a simple English format making it more
accessible to clients whose first language is not English
or who have lower levels of education. The main innova-
tive feature of the programme is that participants aim to
complete a number of tasks that are monitored via ‘task
cards’ marked every day for at least one week. Partici-
pants can choose not to continue with the task if they
found it unhelpful, but they commit to trying it first for
one full week. The tasks include increasing pedometer
targets gradually up to 10,000 steps per day (participants
were provided with an Oregon pedometer PE980), using
a food diary, removing triggers to eating from the envir-
onment, implementing ‘easy switches’ (food swaps),
monitoring hunger levels before and during eating, exer-
cising three times a week, recording instances of saying
“No” to unnecessary food and monitoring weight. Partic-
ipants also receive information about using orlistat (see
below). Sessions also include imparting and testing the
knowledge of caloric content of food. The other key fea-
ture of WAP is the use of a group format focusing on
social support.
The programme comprises 8 weekly group sessions last-
ing one hour each, followed by optional monthly group
meetings. Two advisors trained in WAP delivery con-
ducted the sessions in groups of 10 to 21 participants.
Practice nurse intervention (PNI)
We sought to compare WAP with a ‘best practice’ inter-
vention that could be undertaken in a Primary Healthcare
setting and, in seeking to identify current best-practice, we
conducted a survey of weight management interventions
in six GP surgeries in 2011. Most GPs provided brief advice
and they were then referred on to speak with a practice
nurse. Most nurses provided one -off sessions with some
follow-up, which was typically over a two to eight week
period. A referral to community-based physical activity
programmes was offered in half the surveyed practices.
The PNI incorporated all of the suggested practices to
mimic a more intense model of “best practice”. The nurses
were trained to give the intervention which took place
over eight weeks (4 sessions in total), with the intervention
incorporating national [22] and NHS guidelines.
The nurse provided advice on (1) Diet, e.g. basic intro-
duction to different food groups, how to read food labels
and identify calories in food; limiting the size of the por-
tions of food eaten; and choosing healthier options; (2)
Activity, e.g. finding exercise options they will enjoy and
can do each day; minimise sitting, watching TV (sedentary
activities); encouraged to go to local exercise classes/activ-
ities; and (3) Self-monitoring, i.e. keeping track of eating
habits with a food diary, using a pedometer (this was not
provided), and taking weight at home. Participants also
received a recommendation to use orlistat (see below).
The advice was accompanied by the standard set of
NHS ‘Change4Life’ leaflets [23].
Each session lasted up to 30min.
Both interventions
Both study arms received written information about food
labels and a guide to local physical activity opportunities.
All subjects were given an adapted version of information
on orlistat on the NHS website [24], which at the time of
the study was the only pharmaceutical option for weight
loss. It combines physiological effects and effects on behav-
iour change (avoiding dietary fat). If they wished to use orli-
stat they had to make contact with their GP.
We measured weight in participants at every face-to-
face visit.
Participants were asked to report any other method
used to manage their weight throughout the study period.
Details of the monitoring of the fidelity of each inter-
vention is provided in Additional file 1.
Measures
Measurements were taken at baseline, randomisation,
throughout and at the end of 8 weeks of treatment, and
at the 6 and 12-month follow-up. The following vari-
ables were collected at baseline: Demographic details,
health status, weight loss history, concurrent medica-
tions, height and weight. Waist circumference and blood
pressure (using Omron 705IT BP monitor) were col-
lected at the randomisation session. The International
Physical Activity Questionnaire (IPAQ) [25] was admin-
istered at baseline and the Food craving inventory (FCI),
[26] Use of health services questionnaire, Three Factor
Eating Questionnaire (TFEQ) [27], EQ-5D-5 L (a meas-
ure of health outcomes) [28], and a picture-based Food
Knowledge Assessment (FKA), a tool developed at the
Health and Lifestyle unit to assess knowledge of caloric
content of different food groups were administered at
the randomisation session.
At 2, 6 and 12months, weight, waist circumference,
blood pressure, participant feedback, use of any con-
comitant weight loss treatment, IPAQ, FKA, FCI (also
measured at 1 month), ratings of the intervention re-
ceived and adverse events were collected. In addition,
the TFEQ, EQ-5D and use of health services were col-
lected at the 6 and 12-month follow-up visits.
Outcomes
The primary outcome was the change in weight from
baseline at 12 months. Secondary outcomes included
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proportion of participants losing 5% of body weight,
changes in weight at 2 and 6months, changes in BMI,
changes in waist circumference and blood pressure, and
changes in food knowledge and questionnaire scores.
Statistical analysis
Based on data from similar populations and interven-
tions, we predicted weight loss of WAP 3 kg vs. PNI 0·4
kg in participants who were contacted, with no differ-
ence between treatment arms for participants who were
not available for contact. With 50% of participants available
for follow-up (a conservative estimate), the weight loss dif-
ference would be 1·3 kg (WAP 1·5 kg vs. PNI 0·2 kg). With
SD = 3 in both treatment arms and p < 0.05 (two-sided),
112 participants in each arm would be needed to detect
this difference with 90% power. To minimise clustering ef-
fects due to the group intervention (mean cluster size of 18
and an intra-cluster r = 0·05), 208 participants would be
needed in the WAP arm and 108 in the PNI arm. We
increased this to 220 and 110 participants to achieve an
allocation ratio of 2:1. We therefore aimed to recruit 330
participants.
All analyses were performed using intention-to-treat
(ITT) principle. Participants recorded with at least one
outcome were included in the study arm to which they
were randomised [29]. Analyses accounted for clustering
in both intervention (group or nurse, depending on
treatment arm) [30]. Cluster effect was entered as a ran-
dom intercept as part of a mixed-effects regression
model. All analyses were adjusted for baseline weight,
age, gender, ethnicity, smoking status, and GP practice
as covariates [31, 32]. Missing baseline data were entered
for analysis using mean imputation [33].
A mixed-effects linear regression model was used to
analyse the primary outcome. Weight change at 1, 2, 6
and 12months was included in the model and included a
random intercept for ‘cluster’ (group or nurse, depending
on treatment arm). An unstructured correlation structure,
using restricted maximum likelihood, was used to model
the correlation between data at different time points from
the same participant. Fixed factors included treatment
arm, time point (included as an indicator variable) and
their interaction. Covariates mentioned above were also
included in the model as fixed factors. A Kenward-Roger
degree-of-freedom correction was used.
Several sensitivity analyses were undertaken to check
the robustness of our assumptions regarding missing data
and to check if there was any impact on results of partici-
pants who were identified as pregnant or had bariatric
surgery during the follow-up period (details of these sensi-
tivity analyses and the analysis of all secondary outcomes
are available in the online Additional files 2 and 3).
An online Oracle database was used to enter the data.
Stata (version 14) was used for all analyses.
We estimated NHS health care costs from sources that
included NHS reference costs [34] and Personal Social
Services Research Unit’s (PSSRU) Costs of Health and So-
cial Care [35]. Participants’ responses to the EQ-5D-5 L
questionnaire were used to estimate health states utilities
using the UK value set [36] and Quality-Adjusted Life
Years (QALYs) were estimated across all timepoints. No
discounting was needed as participants were followed-up
post-randomisation for 12months. As per NICE guidance,
the primary endpoint of the cost-effectiveness analysis
were costs, QALYs and the Incremental Cost Effectiveness
Ratio (ICER) (i.e. the ratio of the incremental costs of the
intervention (versus control) over the incremental effect-
ive (versus control). To determine the level of uncertainty
in the joint distribution of cost and QALYs from the two
arms of the study, results were bootstrapped using
10,000 replications and results were presented on a
cost-effectiveness acceptability curves.
Results
Figure 1 shows participant flow through the trial. Partici-
pants were recruited from 24/09/2012 to 31/01/2014.
221 participants were allocated to the intervention group
and 109 to the control group. A total of 291 participants
provided at least one recorded primary outcome meas-
urement (PNI N = 97 (89%); WAP N = 194 (88%)).
Table 1 shows participant characteristics. Reflecting
the intended target population, most participants were
not in paid employment and some 60% belonged to eth-
nic minorities.
A median of 24 participants were allocated per prac-
tice nurse (4 nurses in total). A median of 15 partici-
pants attended the group (15 groups in total). A high
number in both interventions attended at least half of
the treatment sessions (79% WAP versus 69% PNI par-
ticipants), with 65 and 57% of participants attending the
final session at 8-weeks. Very few attended the WAP
maintenance sessions (one in five).
Attendance for follow up was high, with 70% of partic-
ipants followed-up at 12 months. Participants in the PNI
group had slightly increased follow-up rates than the
WAP arm (76% vs. 67% respectively).
The primary outcome analysis showed that participants
in the WAP arm lost significantly more weight (4·2 kg,
SD = 7·3) than those in the PNI arm (2·3 kg, SD = 6·6):
95% CI: -3·7 to − 0·1; p = 0·04. At all time points (except
1-month post randomisation), there was a significantly
greater amount of weight lost in the WAP compared with
the PNI arm (see Table 2).
The results did not change when we used a model that
assumed that data were not missing at random. An ex-
ception to this was if it was assumed that WAP partici-
pants who were lost to follow-up gained more weight
than those lost to follow-up in the PNI arm, or all lost
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to follow-up in either arm had significant weight gain
(i.e. 10 kg). When we used baseline observation for-
ward in all those lost to follow-up, a similar result
was seen (i.e. a greater weight loss in the WAP arm
vs. PNI − 2·4 kg; 95% CI -4·3, − 0·5) (See Fig. 2).
Table 3 shows the results of the complete case ana-
lysis. Participants were included who provided data at
12 months, and an analysis was done which excluded
those pregnant or who had undergone bariatric surgery,
after randomisation which did not substantially alter the
treatment effect.
Among those participants with a recorded outcome
at 12-months, a greater proportion in the WAP arm
had lost at least 5% of body weight, compared with
participants in the PNI arm (41% [61/149] vs. 27% [22/83],
p = 0·004). Waist circumference changes favoured the WAP
Fig. 1 CONSORT diagram
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arm, but not significantly so (− 4·1 cm vs-2·0, p = 0·07).
There were no differences between the study arms in
changes in blood pressure. Participants in the WAP arm
showed a significant increase in their knowledge of the cal-
orie content of foods at the end of treatment and at
6-months, but by 12-months this effect had disappeared.
WAP participants used orlistat more than participants in
the PNI arm (31% vs. 6%; OR = 6·50; 95% CI: 2·78 to 15·59;
p < 0·001) and for those who used orlistat their weight loss
was increased at 12 month follow up (mean − 5·4 kg,
SD = 8·1) compared with those who did not (mean− 2·9 kg,
SD= 6·6; 95% CI for the difference:-4·5 to − 0.4; p= 0·02).
Physical activity levels in both groups increased,
with the WAP arm showing a marginally greater in-
crease (359 vs. 215 MET-minutes/week, 95% CI: -312
to 153; p = 0·18).
At the end of treatment, ratings of helpfulness of both
interventions were high, but WAP received a higher en-
dorsement (9·1 vs. 8·0, p < 0·001) and WAP participants
were also more likely to recommend the programme to
others (9·3 vs. 8·1, p < 0·001). The differences were main-
tained at 12 months (8·4 vs. 7·2, p = 0·001 and 8·8 vs. 7·8,
p = 0·004, respectively).
The full set of secondary outcomes is provided in
Additional file 2.
As the number of clients in each group were simi-
lar, the cost of WAP per client (£195) was similar to
the cost of the PNI (£176). WAP resulted in a mean
incremental gain in QALYs (controlling for baseline
utility and age) of 0·0104 (95% CI: -0·0015 to 0·0224,
p = 0·088) and non-significant mean incremental total
cost was £80 (95% CI: -£505 to £667, p = 0·787). The
base case incremental cost effectiveness ratio was
£7742/QALY indicating that WAP, compared to PNI,
is likely to represent value for money in the NHS.
Based on the power available in this study, the prob-
ability of falling within the NICE threshold for reim-
bursement (£20,000 - £30,000) was between 68 and
77% (Fig. 3).
Discussion
With no significant increase in cost, WAP generated
greater weight loss than PNI. This difference between
groups was evident by the end of the treatment
period and maintained at one year. The results were
not attributable to the control group performing
poorly, as the PNI appears to have outperformed re-
sults in most previous studies [37]. In an evaluation
of the Counterweight Programme [18], 10% of all eli-
gible people lost ≥5% of baseline body weight at
12-month follow-up. In this trial, 27% of people in
the PNI has achieved ≥5% weight loss (41% in the
WAP arm). The differences were robust across different
sensitivity analyses. As a results of being cost neutral but
improving overall health-related quality of life, WAP ap-
pears to be highly cost-effective and this study provide a
good level of certainty WAP would represent value for
money, if deployed within the UK NHS.
The trial had several limitations. Although retention
rates were comparatively good (e.g. Jebb et al. reported
a retention rate of 61% at 12 months [38]), there were
30% of participants at one year who we were unable to
contact. ‘Last observation carried forward’ is often
used to address missing data but one limitation is it
may overestimate treatment effects due to people usu-
ally engaging with a treatment while it is working but
stop when not. We used mixed-effects model ap-
proach and several sensitivity analyses that confirmed
the main result. Dropout rates were also similar in the
Table 1 Sample characteristicss
PNI
(n = 98–109)a
WAP
(n = 197–221)a
Age (years): mean (SD) 45·1 (14·2) 46·6 (15·0)
Female: N (%) 75 (68.8) 161 (72.9)
Married or living with partner N (%) 49 (44.9) 92 (41.6)
Ethnicity: White British N (%) 46 (42.6) 85 (38.0)
Education: A-Level and above N (%) 53 (49.1) 101 (45.7)
In paid employment N (%) 57 (52.3) 103 (46.6)
Entitled to free prescriptions: N (%) 62 (56.9) 133 (60.2)
Current smoker: N (%) 18 (16.5) 35 (15.8)
Weight (kg): mean (SD) 98·3 (16·6) 95·5 (15·8)
BMI: mean (SD) 35·7 (4·3) 35·0 (4·2)
Waist circumference: mean (SD) 114·2 (10·1) 113·4 (10·7)
Systolic blood pressure: mean (SD) 134·8 (15·9) 134·5 (16·7)
Diastolic blood pressure: mean (SD) 80·6 (8·6) 81·3 (10·5)
Number of previous attempts at
weight loss: median (IQR)
3 (2, 5) 3 (1, 5)
Greatest previous amount of weight
loss: median (IQR)
9·3 (5·0, 19·1) 10·9 (6·0, 19·1)
aN varies due to missing data
Table 2 Mean weight loss over 12 months
PN PNI arm
Mean (SD)a
WAP arm
Mean (SD)a
Treatment effect
(95% CI)b
P-value
2 months −2·2 (2·6) -3·2 (2·7) -1·0 (−1·7, −0.3) 0·009
6 months -2·1 (4·3) −5·0 (5·4) −2·5 (−3·8, −1.2) < 0·001
12 months − 2·3 (6·6) −4·2 (7·3) −1·9 (− 3·7, − 0.1) 0·04
aThe total sample used was based on those with a documented weight
measurement at each follow-up time-point. For the PNI arm this was 62, 70, and
83 at 2, 6 and 12months respectively. For the WAP arm it was 144, 141, and 149
bFor the treatment effect, which was calculated using a mixed-effects
regression model, the total sample was 97 and 194, for the PNI and WAP
arms, respectively
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two study arms. Nevertheless, no approach resolves
the missing data problem completely.
As with other weight management programmes and
trials, the participants were predominantly women and
this may limit the generalisability of the results across
genders. We also excluded those who could not speak
English as the WAP programme includes group inter-
action, and this also limits the generalisability of the re-
sults. The simple and clear tasks however made the
programme suitable for participants with English as a
second language.
Trials of behavioural interventions cannot be blind
and expectations may have affected the results if e.g.
participants who believe that they were allocated to in-
ferior treatment are more likely to drop out or partici-
pants in ‘active’ condition receive more attention and
encouragement during post-treatment follow-ups. We
tried to mitigate such effects by presenting the trial as
studying two potentially useful interventions with no indi-
cations of expecting any of them to be superior; and en-
suring that staff collecting outcomes at 6 and 12-month
follow-up were blind to participant allocation. It is re-
assuring that attendance and follow-up rates in the two
study arms were similar.
The sample included a high proportion of participants
from ethnic minorities and participants with limited
socioeconomic resources. Weight management studies,
including those conducted in primary care [39], typic-
ally attract middle class participants and disadvan-
taged groups are normally under- represented [14].
The inclusiveness of this trial can be seen as a posi-
tive factor in evaluating an intervention suitable for
use with under-served populations.
There were no significant change in blood pressure,
this is in line with previous studies. A meta-analysis
which included data from 34 trials, found no change in
either systolic blood pressure with weight loss (18 trials)
nor with diastolic blood pressure (21 trials) [40].
The weight loss achieved was modest, as is com-
mon for all existing weight management approaches
with the exception of bariatric surgery (the one par-
ticipant in the PNI arm who had the procedure lost
34 kg). However, the programme helped over 40% of
participants to achieve a weight loss of at least 5% and
this is expected to convey important health benefits
[13]. Programme participation may also generate
long-term lifestyle changes. PNI participants achieved
their weight loss within the treatment period and
maintained it, while WAP participants continued to
lose weight even after the treatment period ended, al-
though there was some weight regain over the last six
months of follow-up.
There are several candidate explanations for WAP ef-
fects. The WAP condition offered more contact time,
Fig. 2 Treatment effect and 95% CI for change in weight at 12 months under the assumption that non-responders are missing-not-at-random
Table 3 Sensitivity analyses for primary outcome
PNI arm
Mean (SD)
WAP arm
Mean (SD)
Treatment
effect (95% CI)
Complete case analysis
(N = 232)
−2.3 (6.6) −4.2 (7.3) − 2.4 (− 4.9, 0.1)
Excluding participants
who had bariatric surgery
or became pregnant
during follow-upa (N = 221)
− 2.1 (5.7) −4.2 (7.3) −2.1 (− 3.9, − 0.4)
a11 excluded: gastric bypass (PNI 1 (lost 34.2 kg), intervention 0), pregnancy
(PNI 5, intervention 5)
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and there is a belief in the weight management field
that more intensive interventions are more effective.
However, this is not supported by data. A comprehen-
sive meta-analysis found no evidence that more fre-
quent contact generates greater weight loss [11]. This is
similar to findings concerning intensity of contact in
trials of behavioural counselling for smoking cessation
[41]. One possible ‘active ingredient’ of WAP is the group
format providing opportunities for observing other group
members benefiting from concrete strategies, thus
increasing individual’s willingness to persevere with
them as well. Orlistat use provides a good illustra-
tion of this ‘social learning’ effect. Both study arms
were offered orlistat in the same way, but greater
number in the WAP arm opted to use it. This differ-
ence in orlistat use is an intervention effect and so
cannot be controlled for. Clients typically react to
the offer with uncertainty related to the drug’s side
effects. In groups, however, there would usually be
someone who had benefited from the drug in the
past or who opted for the drug and found it benefi-
cial during the programme, and this encouraged
others to try it as well.
Another factor could be the effect of closely monitored
concrete tasks that may improve treatment adherence,
especially in groups with stress levels and lifestyles not
conducive for maintaining difficult behaviour change via
self-motivation alone. Encouraging participants to imple-
ment for at least one week a range of simple behavioural
changes may increase the probability of identifying
those that are manageable and beneficial and transfer
them into routine lifestyle. The camaraderie that typ-
ically develops in WAP groups may represent another
possible factor that facilitates attendance and programme
adherence.
Conclusions
In summary, an easy to disseminate public-domain task-
based weight management programme can provide effect-
ive help to clients across the socioeconomic spectrum and
represent value for money to the NHS.
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